NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Peptide testing

Ordered peptides from Xingtai Jiachuang Technology? Mail in a sample (US only) and let us test it.

Test my supply
+3 more ↓
65%
Finnrick rating
#378 of 500 ranked vendors
46 of 70 classifiable tests passed
methodology · Purity focus
Finnrick analysis

Xingtai Jiachuang Technology's purity-focused record is strongest for GHK-Cu and Retatrutide, though GHK-Cu has thinner volume and Retatrutide has batch-ID gaps. Tirzepatide looks volatile after an improving run, and Tesamorelin plus BPC-157 drive the weak side; the evidence is current and broad but dispersed by peptide.

methodology →
vendor intelligence report
Vendor Intelligence Report: Xingtai Jiachuang Technology

Registry and platform records recast Jiachuang as a new small Hebei entity, not the established facility its marketing describes. The report follows a 35.com storefront, Hong Kong WhatsApp channels, copied GlobalSources boilerplate, and Xingtai cluster leads.

28 pages7 risk factors assessed3 Jul 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
GHK-Cu
$0.06
90%
7
2
Retatrutide
$0.90
74%
19
3
Tirzepatide
$0.45
72%
31
4
BPC-157
$0.45
45%
3
5
Tesamorelin
$3.05
41%
10
7
Ipamorelin
$0.80
-
0
8
PT-141
$0.50
-
0
10
TB-500
$1.10
-
0
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%20 Feb 2026: 63%25 Feb 2026: 64%26 Feb 2026: 64%2 Mar 2026: 64%2 Mar 2026: 64%4 Mar 2026: 65%6 Mar 2026: 65%6 Mar 2026: 65%6 Mar 2026: 65%6 Mar 2026: 65%10 Mar 2026: 65%10 Mar 2026: 65%13 Mar 2026: 65%19 Mar 2026: 65%3 Apr 2026: 66%28 Apr 2026: 66%5 May 2026: 66%20 May 2026: 66%16 Jun 2026: 66%16 Jun 2026: 67%17 Jun 2026: 67%17 Jun 2026: 68%22 Jun 2026: 68%13 Jul 2026: 67%13 Jul 2026: 67%13 Jul 2026: 66%13 Jul 2026: 65%13 Jul 2026: 66%13 Jul 2026: 65%20 Jul 2026: 65%20 Jul 2026: 65%20 Jul 2026: 65%3 Aug 2026: 65%15 Aug 2026: 65%26 Aug 2026: 65%15 Sep 2026: 65%16 Sep 2026: 65%16 Sep 2026: 65%2 Nov 2026: 64%10 Nov 2026: 64%15 Nov 2026: current 65%63%66%65%Feb 26Nov 26
Peptide testing

Ordered peptides from Xingtai Jiachuang Technology? Mail in a sample (US only) and let us test it.

Test my supply
Xingtai Jiachuang Technology test history
COA-backed lab tests
1-10 of 70

About Xingtai Jiachuang Technology test results from Finnrick

Xingtai Jiachuang Technology is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 5 peptides and 70 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible Xingtai Jiachuang Technology peptides in this dataset are BPC-157 (3 tests), GHK-Cu (7 tests) and Retatrutide (19 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 70 recent tests. It also includes 1 correction related to this vendor.

Corrections
2026-07-26
Finnrick data entry
The reported value of 15 mg was inadvertently carried over from a previous Certificate of Analysis (COA) associated with a different sample. This value did not correspond to sample 7f5fe47 and was included in error. The incorrect information has been removed, and the system has been updated to correctly reference the original label claim of 60 mg for this sample.
Peptide testing

Ordered peptides from Xingtai Jiachuang Technology? Mail in a sample (US only) and let us test it.

Test my supply